Anatara Lifesciences Ltd

ANR

AU000000ANR0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:54:56 2024-05-28 EDT			5-day change	1st Jan Change
0.047 ^AUD	+4.44%		+17.50%	+113.64%

05-01	Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	MT
04-09	Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	MT

Anatara Lifesciences Limited Approves Election of Directors

November 11, 2018 at 08:02 pm

Anatara Lifesciences Limited announced that at its AGM held on 12 November 2018, the shareholders approved the election of Ms. Sue MacLeman and Dr. Jane Ryan as directors of the company.

Latest news about Anatara Lifesciences Ltd

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	04-30	MT
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	04-08	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer	12-08	MT
Anatara Lifesciences Ltd Announces Board Changes	23-10-01	CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial	23-09-28	MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One	23-08-30	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23	CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%	23-08-14	MT
Anatara Lifesciences Ltd Announces Registered Office Change	23-04-19	CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS	23-03-09	CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Anatara Lifesciences Ltd Announces board Changes	22-12-06	CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions	22-10-21	MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate	22-10-04	MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement	22-10-03	MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial	22-10-02	CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial	22-08-11	MT
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer	22-06-21	CI
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning	22-06-21	CI
Anatara Lifesciences Expands Criteria for Irritable Bowel Trial	22-05-20	MT
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype	22-05-19	CI
Anatara Lifesciences CEO to Step Down	22-05-05	MT
Anatara Lifesciences Limited Announces Chief Executive Officer Changes	22-05-04	CI

Chart Anatara Lifesciences Ltd

Duration

Period

More charts

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANATARA LIFESCIENCES LTD	+113.64%	5.73M
ELI LILLY AND COMPANY	+37.02%	727B
JOHNSON & JOHNSON	-7.07%	354B
MERCK & CO., INC.	+15.91%	328B
ABBVIE INC.	+0.08%	277B
ASTRAZENECA PLC	+13.85%	243B
NOVARTIS AG	+7.36%	205B
ROCHE HOLDING AG	-6.22%	203B
AMGEN INC.	+4.32%	164B
PFIZER, INC.	-1.51%	164B